NCT05595473View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

March 31, 2029

Study Completion Date

May 31, 2029

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

RZ-001 Dose 1

RZ-001 Dose 1 and VGCV

DRUG

RZ-001 Dose 2

RZ-001 Dose 2 and VGCV

DRUG

RZ-001 Dose 3

RZ-001 Dose 3 and VGCV

DRUG

RZ-001 Dose 4

RZ-001 Dose 4 and VGCV

Trial Locations (5)

41944

Kyungpook National University Hospital, Deagu

06351

Samsung Medical Center, Seoul

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

06591

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

All Listed Sponsors
lead

Rznomics, Inc.

OTHER